Although some observational studies have found a positive association between testosterone levels and physical activity in younger and older men,100,101 others have failed to find an association.102 Many intervention studies specifically designed to assess the effect of physical activity have found increases in testosterone levels following a physical activity intervention.103,104 Age further affects this relationship, as the increase in free testosterone following resistance exercise is significantly diminished in older and middle-aged men, compared to that in younger age groups.105 Extensive data have shown an association between low physical activity levels and cardiovascular risk factors, including metabolic syndrome,93 type 2 diabetes,94 obesity,95 and hypertension.96 The American Heart Association has declared sedentary behaviour to be a modifiable risk factor for CVD and diabetes mellitus,97 and many other organizations recommend physical activity to increase cardiorespiratory fitness.98 Interestingly, in multiple RCTs, this effect of exercise on improved metabolic profile, including fat-free muscle mass and glycemic control, was enhanced by testosterone administration in hypogonadal men.76,99 Unlike the relationship of other cardiovascular risk factors to testosterone levels, the inverse association of testosterone with obesity is well established. As a result of these conflicting results, a recent meta-analysis found no significant association between testosterone therapy and cardiovascular events and mortality, and it reported low-quality evidence due to bias, inconsistencies, and imprecision.34 This disparity in results has led to inconsistencies among clinical practice guidelines. 19 A 2018 meta-analysis of observational studies by Corona et al.19 suggested that low baseline endogenous testosterone levels predicted overall and cardiovascular mortality.
Some men also have a medical condition called hypogonadism, where the body does not make enough testosterone. Test levels are around 600 and e2 around 35.
It can influence how blood vessels tighten or relax, how the heart beats, and how many red blood cells are made. A faster heart rate, or tachycardia, can be a sign of the heart working harder than usual. Prescription drug labels list possible side effects so that patients and doctors can be aware.
It should be noted, however, that none of the individual prostate‐related adverse events significantly differed from those in the placebo group. Calof et al discovered 2 major differences between the testosterone replacement group and the placebo group. Czesla et al performed experiments on latissimus dorsi muscle of sheep by exposing the muscle fibers to metenolone, an analogue of testosterone.145 Czesla et al successfully demonstrated that the muscle specimens that were exposed to metenolone had a significant shift in their composition toward type I muscle fibers. The difference between testosterone and placebo groups in functional class improvement was statistically significant. Although more research is required, there are signals in existing data that suggest testosterone deficiency may play some role in the creation and progression of atherosclerosis. Existing evidence strongly suggests that testosterone plays an important role in the regulation of ventricular repolarization by shortening the length of the QTc interval.
TRT is used to bring testosterone levels back to normal and improve symptoms like fatigue, low sex drive, and depression. Testosterone Replacement Therapy (TRT) is a medical treatment used to help men with low testosterone levels. Until the results of such large‐scale studies become available, we recommend caution when administering testosterone to elderly men. Haddad et al defined adverse cardiovascular events as cardiovascular death, fatal and nonfatal myocardial infarction, angina, arrhythmia, revascularization procedures, and stroke. The effects of testosterone replacement on different lipoprotein subfractions have been reported in a previous section of this review article. Haddad et al performed a meta‐analysis of 30 placebo‐controlled randomized trials, which included 808 men in the testosterone replacement group and 834 men in the placebo group.31 The authors found no changes in systolic or diastolic blood pressure with testosterone replacement. When all the above‐mentioned cardiovascular events were pooled, Calof et al still did not find a statistically significant difference between the 2 groups.
Finally, Haddad et al used only 6 articles to perform their meta‐analysis for adverse cardiovascular events, which included 161 men in the testosterone replacement group and 147 men in the placebo group. Calof et al did not find a significant difference in the rate of cardiovascular events between the testosterone replacement group and the placebo group.146 Specifically, the authors found no statistically significant differences between the 2 groups in the rates of atrial fibrillation, atrial arrhythmia, myocardial infarction, chest pain or ischemia, coronary procedures including coronary artery bypass grafting, vascular events, and cerebrovascular events. Therefore, it is reasonable to assume that reduced levels of testosterone in CHF patients would result in decreased exercise capacity. Although testosterone was shown to significantly improve exercise capacity, none of the studies found a significant change in the LVEF.140–143 New York Heart Association class was shown to improve in 2 of the studies included in the meta‐analysis.144 Thirty‐five percent of the patients in the testosterone group (20 of 57) experienced an improvement of ≥1 New York Heart Association class in their functional capacity compared with only 9.8% of patients in the placebo group (5 of 51). Interestingly, Jankowska et al also discovered that the only predictor of the extent of deterioration in exercise capacity, as measured by peak VO2 and peak O2 pulse, was the magnitude of reduction in circulating testosterone levels. Not only did Jankowska et al demonstrate that men with CHF have significantly reduced levels of total and free testosterone, the authors were also able to demonstrate that with worsening severity of CHF, there was a significant stepwise decrease in the levels of both total testosterone and estimated free testosterone. In a study of 208 men with CHF and a median left ventricular ejection fraction (LVEF) of 33%, Jankowska et al demonstrated a statistically significant prevalence of testosterone deficiency among men with CHF who were either ≤45 or ≥66 years old.137 Levels of estimated free testosterone were also shown to be significantly reduced among CHF patients.